ARCTURUS THERAPEUTICS HOLDINGS INC. Increase Decrease In Operating Lease Liability
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Increase Decrease In Operating Lease Liability of -$1.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$714.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.10M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.08M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.07M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for fiscal 2025 was -$4.21M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for fiscal 2024 was -$3.65M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for fiscal 2023 was -$4.31M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase decrease in operating lease liability for fiscal 2022 was -$4.48M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$714.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.82M 10-Q · filed 2026-08-06 | -$2.90M derived: sum of 3 quarters · filed 2026-08-06 | -$3.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.10M 10-Q · filed 2026-05-07 | -$2.19M derived: sum of 2 quarters · filed 2026-05-07 | -$3.25M derived: sum of 3 quarters · filed 2026-05-07 | -$4.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$2.15M derived: sum of 2 quarters · filed 2026-03-03 | -$3.20M derived: sum of 3 quarters · filed 2026-08-06 | -$4.21M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.12M derived: sum of 2 quarters · filed 2026-08-06 | -$3.13M 10-Q · filed 2025-11-12 | -$4.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.06M 10-Q · filed 2026-08-06 | -$3.05M derived: sum of 3 quarters · filed 2026-08-06 | -$4.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.01M 10-Q · filed 2026-05-07 | -$2.00M derived: sum of 2 quarters · filed 2026-05-07 | -$2.98M derived: sum of 3 quarters · filed 2026-05-07 | -$3.67M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.97M derived: sum of 2 quarters · filed 2026-03-03 | -$2.65M derived: sum of 3 quarters · filed 2026-03-03 | -$3.65M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$977.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.67M derived: sum of 2 quarters · filed 2025-11-12 | -$2.66M 10-Q · filed 2025-11-12 | -$3.77M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.68M 10-Q · filed 2025-08-11 | -$2.79M derived: sum of 3 quarters · filed 2026-03-03 | -$3.88M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$991.00K 10-Q · filed 2025-05-12 | -$2.10M derived: sum of 2 quarters · filed 2026-03-03 | -$3.19M derived: sum of 3 quarters · filed 2026-03-03 | -$4.27M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$2.20M derived: sum of 2 quarters · filed 2026-03-03 | -$3.28M derived: sum of 3 quarters · filed 2026-03-03 | -$4.31M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$2.17M derived: sum of 2 quarters · filed 2024-11-07 | -$3.20M 10-Q · filed 2024-11-07 | -$4.20M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$2.10M 10-Q · filed 2024-08-05 | -$3.11M derived: sum of 3 quarters · filed 2025-03-06 | |
| 2023-03-31 | -$1.03M 10-Q · filed 2024-05-08 | -$2.03M derived: sum of 2 quarters · filed 2025-03-06 | ||
| 2022-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$4.48M 10-K · filed 2025-03-06 | ||
| 2022-09-30 | -$3.48M 10-Q · filed 2023-11-14 | |||
| 2022-03-31 | -$445.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$1.35M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |